Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fakhravac versus Sinopharm COVID-19 vaccine trial in adults
IRCT20210206050259N3Phase 3Completed
- Sponsor
- Organization of Defensive Innovation and Research
- Start
- Sep 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of FINCoVac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Organization of Defensive Innovation and Research. Primary endpoint: Occurrence of confirmed COVID-19 disease two weeks after second dose. Started Sep 2021; status: completed.
02
Drugs
FINCoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210206050259N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210206050259N3.